观察了苦木内酯甲(nigakinone A)治疗高血压病136例,并设降压灵29例作双盲对照。结果治疗组总有效率为84.5％,对照组总有效率为79％。动物实验证明其降压作用部位在中枢,可能属α受体兴奋剂。用药前、后心电图、肝肾功能、血象对比证明对心、肝、肾、血象等无明显毒性损害。我们认为该药具有剂量小、毒副作用少、降压疗效显著等优点,值得扩大临床使用和研究。 Thirty-six cases of hypertensive patients treated with nigakinone A were observed, and 29 cases of Jianglingling were treated as double-blind control. Results The total effective rate was 84.5% in the treatment group and 79% in the control group. Animal experiments show that the site of antihypertensive effect in the center, may belong to α receptor agonists. Before treatment, after electrocardiogram, liver and kidney function, blood contrast proved no significant toxicity of heart, liver, kidney, blood and other damage. We believe that the drug has the advantages of small dose, less toxic side effects, significant effect of antihypertensive effect, and is worth expanding clinical use and research.